<DOC>
	<DOCNO>NCT00726323</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine best confirm response rate , safety , tolerability GSK1363089 treatment papillary renal cell carcinoma . Papillary renal cell carcinoma may classify hereditary sporadic form ; subject either classification accept study .</brief_summary>
	<brief_title>A Phase II Study GSK1363089 ( Formerly XL880 ) Papillary Renal-Cell Carcinoma ( PRC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Histologically confirm diagnosis PRC metastatic disease bilateral multifocal renal tumor localize kidney . Measurable disease , ECOG performance status &lt; /= 2 . Adequate bone marrow reserve , hepatic , renal , cardiovascular function . Radiation &gt; /=25 % bone marrow within 14 day GSK1363089 , 1 prior anticancer therapy , receive prior treatment cmet inhibitor , brain metastasis , Any uncontrolled intercurrent illness , Pregnant breastfeeding , HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>c-Met</keyword>
	<keyword>Papillary Renal Cell Carcinoma ( PRC )</keyword>
	<keyword>Sporadic papillary renal cell carcinoma ,</keyword>
	<keyword>Clear cell renal carcinoma</keyword>
	<keyword>Hereditary papillary renal cell carcinoma ,</keyword>
</DOC>